Summary
The prevalence of 1) hepatitis C virus (HCV), an agent likely to be responsible for parenter transmitted hepatitis non-A, non-B, 2) hepatitis B virus (HBV) and 3) human immunodeficiency virus (HIV) infection was studied in 211 patients with clotting disorders(78% of the patients had residual factor activities of ≤2%). Of these patients 71% were positive for HBV markers and 44% for HIV markers. Using a new ELISA technique, 80% were anti-HCV-positive. The prevalence of anti-HCV was greater in patients with more severe clotting disorders and was related to the total amount of replacement therapy received; the prevalence was less in older patients. Seroconversion after a single exposure to dry heat-treated factor concentrates was documented in 3 patients 3–4 months after exposure.
This is a preview of subscription content, log in via an institution to check access.
References
Aach RD, Szmuness W, Mosley JW, Hollinger FB, Kahn RA, Stevens CE, Edwards VM, Werch J (1981) Serum alanine aminotransferase of donors in relation to the risk of non-A,non-B hepatitis in recipients. N Engl J Med 304: 989–994
Alter HJ, Holland PV, Morrow AG, Purcell RH, Feinstone SM, Moritsugu Y (1975) Clinical and serological analysis of transfusion-associated hepatitis. Lancet II: 838–841
Choo Q-L, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M (1989) Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244: 359–361
Dienstag JL (1983) Non-A,non-B hepatitis. I. Recongnition, epidemiology and clinical features. Gastroenterology 85: 439–462
Gürtler L, Wemicke D, Eberle J, Zulek G, Deinhardt F, Schramm W (1984) Increase in prevalence of anti-HTLV III in hemophiliacs. Lancet I: 1275–1276
Gürtler LG, Schramm W, Weissner J, Krauss-Dietz B (1986) Ungeklärte HIV Serokonversionen nach Substitution mit hitzeinaktivierten Faktorenkonzentraten — Probleme der Kausalitätsabklärung —. In: Landbeck G, Schimpf K (eds) 3. Rundtischgespräch über aktuelle Probleme der Substitutionstherapie Hämophiler. Springer Berlin Heidelberg New York London Paris Tokyo, pp 51–59
Gürtler LG, Eberle J, Lorbeer B, Deinhardt F (1987) Sensitivty and specifity of commercial ELISA kits for screening anti-LAV/HTLV II. J Virol Methods 15: 11–23
Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, Miyamura T, Dienstag JL, Alter MJ, Stevens CE, Tegtmeier GE, Bonino F, Colombo M, Lee WS, Kuo C, Berger K, Shuster JR, Overby LR, Bradley DW, Houghton M (1989) An assay for circulating antibodies to a major etiologic virus of human non-A,non-B hepatitis. Science 244: 362–364
Roggendorf M, Deinhardt F, Rasshofer R, Eberle J, Hopf U, Möller B, Zachoval R, Pape G, Schramm W, Rommel F (1989) Antibodies to hepatitis C virus (anti-HCV). Lancet (in press)
Stehr-Green JK, Holman RC, Jason JS, Evatt BL (1988) Hemophilia-associated AIDS in the United States, 1981 to September 1987. Am J Public Health 78: 439–442
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schramm, W., Roggendorf, M., Rommel, F. et al. Prevalence of antibodies to hepatitis C virus (HCV) in haemophiliacs. Blut 59, 390–392 (1989). https://doi.org/10.1007/BF00321210
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00321210